This Kalorama Information report focuses on several key product segments of neurotherapeutic treatment:

• Alzheimer’s Disease and Other Dementias
• Brain and Neurologic Cancers
• Brain Trauma and Stroke
• Movement Disorders
• Seizure Disorders and Epilepsy
• Spinal Cord and Peripheral Nerve Disorders
• Other Neurological Conditions and Disorders

The report covers both currently marketed and late-stage development neurotherapeutic products in detail. Revenues for each segment were generated using dollar and unit sales for each product.

The report includes statistical information for selected neurological conditions and diseases by type worldwide, with special emphasis on the U.S. market. The market segments provide an overview, description of products on the market, description of products in development, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

All market data pertain to the world market at the manufacturers’ level. The base year for data was 2004. Historical data are provided for the years 2002 and 2003, with forecast data provided for 2005 through 2009. Compound annual growth rates (CAGRs) are provided for the 2002-2004, 2004-2009 and 2002-2009 periods for each industry segment covered. Competitive analysis is provided for the year 2004. The forecasted market analysis for 2005-2009 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends.

Diseases addressed in this study include:

• Alzheimer’s Disease
• Amyotrophic Lateral Sclerosis
• Bell’s Palsy
• Traumatic Brain Injury (TBI)
• Brain and Spinal Tumors
• Carpal Tunnel Syndrome
• Cerebral Palsy
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Creutzfeldt-Jakob Disease
• Epilepsy
• Guillain-Barre Syndrome
• Huntington’s Disease
• Migraine Headaches
• Motor Neuron Diseases
• Multi-Infarct Dementia
• Multiple Sclerosis
• Myasthenia Gravis
• Neurofibromatosis
• Parkinson’s Disease
• Spinal Cord Injury
• Stroke

Related Reports:
Snapshots US Pharmaceuticals 2009
Mapping the Healthcare Landscape Bringing pharmaceuticals into focus
Dealmaking and Industry Outlook: Neurological Disease
Pharmaceutical Industry in the United States - Porter’s Five Forces Strategy Analysis
Pharmaceuticals Industry Report
Pharmaceutical Industry in Mexico
CDK Inhibitors Patent Landscape 2009
Commercial Insight: Antipsychotics - Revenues of depots and new agents will partially offset generic erosion
Antipsychotics Market Forecast
Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes